Clearside Biomedical Announces Multiple Presentations on Suprachoroidal Delivery to be Featured at the 25th EURETINA Congress
Clearside Biomedical (Nasdaq: CLSD) announced multiple presentations featuring its SCS Microinjector® platform at the upcoming 25th EURETINA Congress in Paris from September 4-7, 2025. The presentations will highlight the company's suprachoroidal delivery platform designed for treating various retinal diseases including wet AMD, diabetic retinopathy, and geographic atrophy.
Key presentations include Phase 2b results from the ODYSSEY trial and Phase 3 program updates for CLS-AX in neovascular age-related macular degeneration, presented by Dr. Sobha Sivaprasad. Dr. Victor Chong, Chief Medical Officer, will present a decade-long review of suprachoroidal drug delivery evolution and participate in a panel discussion on geographic atrophy at the Ophthalmology Futures Retina Forum.
Clearside Biomedical (Nasdaq: CLSD) ha annunciato diverse presentazioni che illustreranno la sua piattaforma SCS Microinjector® al 25º Congresso EURETINA che si terrà a Parigi dal 4 al 7 settembre 2025. Le sessioni metteranno in luce la tecnologia di somministrazione suprachoroidale sviluppata per il trattamento di diverse patologie retiniche, tra cui AMD umida, retinopatia diabetica e atrofia geografica.
Tra gli interventi principali figurano i risultati di fase 2b dallo studio ODYSSEY e gli aggiornamenti sul programma di fase 3 per CLS-AX nella degenerazione maculare neovascolare, presentati dalla Dr.ssa Sobha Sivaprasad. Il Dr. Victor Chong, Chief Medical Officer, presenterà una rassegna decennale sull’evoluzione della somministrazione suprachoroidale dei farmaci e parteciperà a una tavola rotonda sull’atrofia geografica durante l’Ophthalmology Futures Retina Forum.
Clearside Biomedical (Nasdaq: CLSD) anunció múltiples presentaciones que mostrarán su plataforma SCS Microinjector® en el 25.º Congreso de EURETINA en París, del 4 al 7 de septiembre de 2025. Las presentaciones destacarán la plataforma de administración suprachoroidea diseñada para tratar diversas enfermedades de la retina, incluyendo AMD exudativa, retinopatía diabética y atrofia geográfica.
Entre las presentaciones clave están los resultados de fase 2b del ensayo ODYSSEY y las actualizaciones del programa de fase 3 para CLS-AX en degeneración macular neovascular, que presentará la Dra. Sobha Sivaprasad. El Dr. Victor Chong, Director Médico, ofrecerá una revisión de la evolución de la administración suprachoroidea en la última década y participará en un panel sobre atrofia geográfica en el Ophthalmology Futures Retina Forum.
Clearside Biomedical (나스닥: CLSD)는 2025년 9월 4일부터 7일까지 파리에서 열리는 제25회 EURETINA 학회에서 자사의 SCS Microinjector® 플랫폼 관련 여러 발표를 진행한다고 발표했습니다. 발표에서는 습성 AMD, 당뇨병성 망막병증, 지리적 위축 등 다양한 망막 질환 치료를 위해 설계된 초망막(슈프라코로이달) 약물 전달 플랫폼을 소개합니다.
주요 발표로는 ODYSSEY 시험의 2b상 결과와 신생혈관성 연령관련황반변성 치료제 CLS-AX의 3상 프로그램 업데이트가 있으며, 이는 소바 시바프라사드 박사가 발표합니다. 빅터 총(Victor Chong) 의학책임자는 초망막 약물 전달의 10년간 발전사를 발표하고 Ophthalmology Futures Retina Forum에서 지리적 위축 관련 패널 토의에 참여할 예정입니다.
Clearside Biomedical (Nasdaq: CLSD) a annoncé plusieurs présentations mettant en avant sa plateforme SCS Microinjector® lors du 25e congrès EURETINA à Paris, du 4 au 7 septembre 2025. Les interventions mettront en lumière la plateforme d’administration suprachoroïdienne destinée au traitement de diverses maladies de la rétine, y compris la DMLA exsudative, la rétinopathie diabétique et l’atrophie géographique.
Parmi les présentations clés figurent les résultats de phase 2b de l’essai ODYSSEY et les mises à jour du programme de phase 3 pour CLS-AX dans la dégénérescence maculaire néovasculaire, présentés par la Dre Sobha Sivaprasad. Le Dr Victor Chong, Chief Medical Officer, présentera une revue de dix ans de l’évolution de l’administration suprachoroïdienne et participera à une table ronde sur l’atrophie géographique lors de l’Ophthalmology Futures Retina Forum.
Clearside Biomedical (Nasdaq: CLSD) gab mehrere Präsentationen zu seiner SCS Microinjector®-Plattform auf dem 25. EURETINA-Kongress in Paris vom 4. bis 7. September 2025 bekannt. Die Beiträge werden die suprachoroidale Applikationsplattform des Unternehmens hervorheben, die zur Behandlung verschiedener Netzhauterkrankungen wie feuchter AMD, diabetischer Retinopathie und geografischer Atrophie entwickelt wurde.
Zu den Schwerpunkten zählen die Phase-2b-Ergebnisse der ODYSSEY-Studie sowie Updates zum Phase-3-Programm für CLS-AX bei neovaskulärer altersbedingter Makuladegeneration, präsentiert von Dr. Sobha Sivaprasad. Dr. Victor Chong, Chief Medical Officer, wird einen zehnjährigen Überblick über die Entwicklung der suprachoroidalen Wirkstoffapplikation geben und an einer Paneldiskussion zur geografischen Atrophie im Ophthalmology Futures Retina Forum teilnehmen.
- None.
- None.
Insights
Clearside's upcoming presentations on suprachoroidal delivery platform and CLS-AX program represent important clinical progress for their retinal disease pipeline.
Clearside Biomedical is advancing its innovative suprachoroidal delivery platform with multiple presentations scheduled at the upcoming EURETINA Congress. The company's SCS Microinjector® technology enables targeted drug delivery to the back of the eye, potentially addressing multiple retinal diseases including wet AMD, diabetic retinopathy, diabetic macular edema, geographic atrophy and ocular cancer.
Most significantly, the company will present Phase 2b results from the ODYSSEY trial for CLS-AX (axitinib injectable suspension) in neovascular age-related macular degeneration alongside details about their Phase 3 program design, which has received FDA alignment. This progression to late-stage development indicates the company is advancing its lead candidate through the regulatory pathway.
Clearside is also expanding its pipeline with a new streamlined Phase 2 trial in non-proliferative diabetic retinopathy, demonstrating pipeline diversification beyond their initial wet AMD focus. The company's partnership with REGENXBIO for suprachoroidal gene therapy delivery (ALTITUDE study) further validates their platform technology.
The presentations' focus on geographic atrophy is particularly noteworthy, as this represents a significant unmet medical need with growing market potential as the population ages. The company believes their approach may improve efficacy for small molecules and complement inhibition while potentially reducing systemic and anterior segment side effects - addressing key challenges in current treatment options.
These developments collectively showcase Clearside's progress in leveraging their proprietary delivery platform across multiple high-value retinal indications, potentially expanding their addressable market and clinical relevance.
- Presentations Highlight the Versatility of Clearside’s SCS Microinjector® Platform for the Treatment of Multiple Retinal Diseases -
- CLS-AX Trial Designs in Wet AMD and Diabetic Retinopathy to be Featured in Presentation by Dr. Sobha Sivaprasad -
ALPHARETTA, Ga., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its SCS delivery platform and CLS-AX program will be highlighted in multiple presentations at the 25th EURETINA Congress from September 4 - 7, 2025 in Paris, France. Victor Chong, MD, MBA, Chief Medical Officer and EVP, Head of Research and Development will also participate in a panel discussion at the preceding Ophthalmology Futures Retina Forum on September 3, 2025.
Clearside’s suprachoroidal delivery platform is designed to enable targeted treatment for multiple retinal diseases, including wet AMD, diabetic retinopathy, diabetic macular edema, geographic atrophy and ocular cancer.
“We are excited to showcase our SCS Microinjector® platform and advancements with our CLS-AX program at these prominent medical meetings in Europe,” said Dr. Chong. “For CLS-AX, we have designed a Phase 3 trial in wet AMD in alignment with the U.S. FDA, and a new, streamlined Phase 2 trial design in non-proliferative diabetic retinopathy. In addition, we believe suprachoroidal delivery has the potential to provide a targeted approach for the treatment of geographic atrophy, enabling drug dispersion directly to the choroid and retina while potentially minimizing systemic and anterior segment side effects. This method may offer improved efficacy for small molecules and complement inhibition in both the retinal pigment epithelium and choroid,” Dr. Chong concluded.
25th EURETINA Congress
Title: Suprachoroidally Administered CLS-AX in Participants with Neovascular Age-Related Macular Degeneration: Phase 2b Results from ODYSSEY and Phase 3 Program Update
Presenter: Sobha Sivaprasad, MD, Professor of Retinal Clinical Research, Consultant Ophthalmologist, Moorfields Eye Hospital, London, UK
Date: Saturday, September 6, 2025, 16:06 - 16:12 CEST
Title: A Decade-Long Review of the Evolution of Suprachoroidal Drug Delivery with a Focus on Axitinib Injectable Suspension for Neovascular Age-Related Macular Degeneration
Presenter: Victor Chong, MD, MBA, Chief Medical Officer and EVP, Head of Research and Development
Date: Saturday, September 6, 2025, 14:27 - 14:33 CEST
Partner: REGENXBIO
Title: Suprachoroidal gene therapy for diabetic retinopathy (ALTITUDE study)
Presenter: Lejla Vajzovic, MD, Associate Professor of Ophthalmology at Duke University School of Medicine
Date: Thursday, September 4, 2025, 11:13 - 11:20 CEST
Ophthalmology Futures Retina Forum
Title: Geographic Atrophy & Intermediate AMD: Lessons Learned from Glaucoma & Other Chronic Disease
Panelist: Victor Chong, MD, MBA, Chief Medical Officer and EVP, Head of Research and Development
Date: Wednesday, September 3, 2025, 18:40 - 19:10 CEST
About CLS-AX (axitinib injectable suspension)
CLS-AX (axitinib injectable suspension) is a proprietary suspension of axitinib for suprachoroidal injection. Axitinib is a tyrosine kinase inhibitor (TKI), currently approved as an oral tablet formulation to treat advanced renal cell carcinoma, that achieves pan-VEGF blockade, directly inhibiting VEGF receptors-1, -2, and -3 with high potency and specificity. Clearside believes this broad VEGF blockade may have efficacy advantages over existing retinal therapies by acting at a different level of the angiogenesis cascade and may benefit patients who sub-optimally respond to current, more narrowly focused anti-VEGF therapies. Suprachoroidal injection of this proprietary suspension of axitinib has demonstrated meaningful potential in Phase 1/2a and Phase 2b wet AMD clinical trials in which CLS-AX was well tolerated and demonstrated a positive safety profile. With suprachoroidal administration of axitinib, there is the potential to achieve prolonged duration and targeted delivery to affected tissue layers by compartmentalizing axitinib behind the retina, thereby limiting drug exposure to the front of the eye.
About Clearside’s Suprachoroidal Space (SCS®) Injection Platform and SCS Microinjector®
Clearside’s patent protected, proprietary suprachoroidal space (SCS®) injection treatment approach offers unprecedented access to the back of the eye, where sight-threatening disease often occurs. The Company’s unique platform is inherently flexible and intended to work with established and new formulations of medications. Clearside’s patented SCS Microinjector® can deliver a wide variety of drug candidates into the suprachoroidal space, providing targeted delivery to potentially improve efficacy and compartmentalization of medication to reduce or eliminate toxic effects on non-diseased cells. The SCS Microinjector is comprised of a syringe with a custom-designed hub and two 30-gauge hollow microneedles of varying lengths, each approximately one millimeter, optimizing insertion and suprachoroidal administration of drugs.
About Clearside Biomedical, Inc.
Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®) to improve patient outcomes. Clearside’s SCS injection platform, utilizing the Company’s patented SCS Microinjector®, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside has a pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company’s lead program, CLS-AX (axitinib injectable suspension), is a Phase 3 ready asset for the treatment of neovascular age-related macular degeneration (wet AMD). Clearside developed and gained approval for its first product, XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the U.S. through a commercial partner. Clearside also strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. For more information, please visit clearsidebio.com or follow us on LinkedIn and X.
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe”, “expect”, “may”, “plan”, “potential”, “will”, and similar expressions, and are based on Clearside’s current beliefs and expectations. These forward-looking statements include statements regarding the clinical development of Clearside’s product candidates, and the potential benefits of CLS-AX, Clearside’s suprachoroidal delivery technology and Clearside’s SCS Microinjector®. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, Clearside’s reliance on third parties over which it may not always have full control, Clearside's ability to raise additional capital, and other risks and uncertainties that are described in Clearside’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (SEC) on March 27, 2025, Clearside’s Quarterly Report on Form 10-Q filed with the SEC on August 8, 2025 and Clearside’s other periodic reports filed with the SEC. Any forward-looking statements speak only as of the date of this press release and are based on information available to Clearside as of the date of this release, and Clearside assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
Source: Clearside Biomedical, Inc.
Investor and Media Contact: ir@clearsidebio.com
FAQ
What will Clearside Biomedical (CLSD) present at EURETINA Congress 2025?
What retinal diseases can Clearside's suprachoroidal delivery platform potentially treat?
When and where will CLSD's presentations take place at EURETINA 2025?
What are the potential advantages of Clearside's suprachoroidal delivery method?
Who are the key presenters for Clearside at EURETINA 2025?
